ArticleInternational journal of women's health2026
"When a Thorn Comes Into Your Body, You Must Remove It". A Socio-Ecological Analysis of the Acceptability of Intravaginal Artesunate as Cervical Precancer Treatment in a Phase 1 Clinical Trial.
Article in International journal of women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06165614 (Self-administered Artesunate Pessaries for Treatment of Cervical Precancer in Kenya), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Self-administered Artesunate Pessaries for Treatment of Cervical Precancer in Kenya
Who cites it
1 citing paper in PubMed.
- Trying to Heal Without "Bringing Problems": Navigating Cervical Precancer Stigma in a Phase I Clinical Trial in Western Kenya.medRxiv : the preprint server for health sciences · 2025Article
Corrections and comments
- Update of
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Innovative strategies are crucial to meet the World Health Organization's 90/70/90 cervical cancer elimination targets and to prevent millions of deaths by 2030. Women in low-and middle-income countries (LMICs) bear the greatest burden of cervical cancer yet have limited access to cervical precancer treatment. Scalable solutions, such as self-administered intravaginal therapies, can help close this treatment gap. In an ongoing Phase 1 trial of intravaginal artesunate pessaries as primary treatment for cervical intraepithelial neoplasia grade 2 or 3 (CIN 2/3), we evaluated the acceptability of this intervention among trial participants. Methods: Seventeen participants completed in-depth interviews in their preferred language, focusing on their experiences with artesunate self-administration and contextual factors that impacted acceptability. We conducted a thematic analysis using the socioecological framework to analyze product, individual, partner, community, and cultural factors related to acceptability of intravaginal artesunate. Results: Participants in this Phase 1 trial were primarily low-income women with limited formal education, and the majority were also living with HIV and had been on antiretrovirals for over a decade. Despite minimal prior experience with vaginal self-administration of medication, participants found the pessary acceptable and were highly motivated to get treatment for cervical precancer. Social support, educational interventions, and faith were crucial in enabling participants to complete the treatment protocol successfully. Conclusion: Kenyan women found self-administered intravaginal artesunate for treating CIN2/3 to be highly acceptable. Randomized studies of intravaginal artesunate and other topical therapies are needed to further evaluate their efficacy and acceptability in LMICs. Clinical Trials Registration: Clinicaltrials.gov NCT06165614.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.